BLAINJECTIONINJECTABLEPriority Review
Approved
Apr 2021
Lifecycle
Peak
Competitive Pressure
30/100
Clinical Trials
20
Data completeness
6/8 — Strong
Priority Review
JEMPERLI (dostarlimab) by GSK is programmed death receptor-1-directed antibody interactions [moa]. Approved for programmed death receptor-1 blocking antibody [epc]. First approved in 2021.
Drug data last refreshed Yesterday · AI intelligence enriched 6d ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
JEMPERLI (dostarlimab) is a PD-1 blocking monoclonal antibody approved in 2021 for mismatch repair-deficient (dMMR) endometrial cancer. It works by inhibiting programmed death receptor-1 interactions, enabling the immune system to recognize and attack cancer cells. The drug represents a key immunotherapy option in the PD-1 inhibitor class.
$0.002BPart D
PeakJEMPERLI is in peak lifecycle with modest Part D penetration ($2M annually), indicating a smaller specialty market with targeted field team requirements.
Mechanism of Action
Programmed Death Receptor-1-directed Antibody Interactions
Pharmacologic Class:
Programmed Death Receptor-1 Blocking Antibody
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Clinical Trials (20)
XELOX Plus DoSTARlimab Versus XELOX Alone as Consolidation Treatment After Standard Chemoradiation in pMMR/MSS or MSI-Low Locally Advanced Rectal Cancer (LARC) Patients
Started Jan 2026
270 enrolled
Locally Advanced Rectal Cancer (LARC)
A Study of Dostarlimab in Combination With Carboplatin-paclitaxel in Chinese Participants With Primary Advanced or Recurrent Endometrial Cancer (EC)
Started Nov 2025
30 enrolled
Neoplasms, Endometrial
Clinical Trial to Assess the Efficacy of Dostarlimab as Neoadjuvant Therapy in Patients With MMRd/MSI-H Stage II-III Endometrial Cancer
Started Oct 2025
25 enrolled
MMRd/MSI-H Stage II-III Endometrial Cancer
pReOperative Dostarlimab and Novel Therapies in EndOmetrial Cancer
Started Sep 2025
40 enrolled
Endometrial Cancer
A Study to Evaluate the Safety of Dostarlimab in Adult Participants in India With Recurrent or Advanced Endometrial Cancer (EC)
Started Jul 2025
100 enrolled
Neoplasms, Endometrial
Worked on JEMPERLI at GSK? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.